Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06660 艾美疫苗
Listing Date2022/10/06
Listing Price16.160
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    5 lot
  • One Lot Success Rate

AIM Vaccine Co. is a major vaccine company in China. It is the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), accounting for a 7.4% market share. In terms of 2021 sales revenue, it accounted for a 2.1% market share in the PRC.

The Group has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies.

The Group currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are market-leading key commercialized vaccine products.

The Group also have 22 vaccine candidates against 13 disease areas, of which five candidates are at clinical stages. It is expected to launch at least four from 2023 to 2025. Substantially all of customers were provincial-level and county-level CDCs.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
No. of Offer Shares9.71M H shares
No. of International Offer Shares8.74M H shares
No. of HK Offer Shares0.97M H shares
Offer Price$16.16
Stock Code6660
Sponsor(s)Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited, Macquarie Capital Limited
Underwriter(s)Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited, Macquarie Capital Limited, BOCI Asia Limited, ICBC International Securities Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Livermore Holdings Limited
Application PeriodSep 23 (Fri) - noon, Sep 28 (Wed)
Price Determination Date--
Result Announcement DateOn or before Oct 05 (Wed)
Result Announcement DateOn or before Oct 05 (Wed)
Dealings in Shares commence onOct 06, 2022. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$16.16
Capitalization (H Shares)19.55B
NAV / share ($)$2.93 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 16.16, the net proceeds raised would be HKD 70.01M, of which
60% : Advance R&D of vaccine candidates and enrich vaccine pipeline
35% : Construction of new production facilities
5% : Expand sales and marketing team
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.